2019
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals Of Oncology 2019, 30: 310-316. PMID: 30566587, PMCID: PMC6386026, DOI: 10.1093/annonc/mdy541.Peer-Reviewed Original ResearchConceptsNon-aspirin nonsteroidal anti-inflammatory drugsNonsteroidal anti-inflammatory drugsEndometrial Cancer ConsortiumEndometrial cancerAnti-inflammatory drugsObese womenOdds ratioCancer ConsortiumStudy-specific odds ratiosLogistic regressionStandard-dose aspirinUse of aspirinUse of acetaminophenConfidence intervalsTimes/weekCase-control studyRisk of cancerMixed-effects logistic regressionLow-dose formulationsLeast weekly useNormal weightPooled analysisInverse associationStratified analysisReduced risk
2018
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjorge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, deFazio A, Dennis J, Diez O, Domchek SM, Dörk T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Edwards DV, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research 2018, 78: 5419-5430. PMID: 30054336, PMCID: PMC6139053, DOI: 10.1158/0008-5472.can-18-0951.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesNovel lociGWAS lociCausal genesMajority of GWASTranscriptome-wide association studyAssociation studiesGenotype-Tissue Expression (GTEx) projectLarge-scale genome-wide association studiesHigh-density genotyping dataPlausible causal genesPotential novel lociNovel genetic lociGWAS-identified variantsRNA sequencing dataDisease susceptibility variantsBonferroni-corrected significance levelTranscriptomic analysisExpression projectGenetic lociSummary statistics dataRisk lociGene expressionSequencing dataGenes
2017
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA, Group O. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecologic Oncology 2017, 145: 346-351. PMID: 28314588, DOI: 10.1016/j.ygyno.2017.02.032.Peer-Reviewed Original ResearchConceptsBRCA mutation carriersOvarian cancer patientsOvarian cancerBreast cancerMutation carriersPreventive mastectomyCancer patientsActuarial riskStage III/IV ovarian cancerUnaffected BRCA mutation carriersEarly-stage ovarian cancerBreast cancer incidenceStage ovarian cancerMutation-carrying patientsProportional hazards modelCause of mortalityImpact of mastectomyOvarian cancer diagnosisProbability of deathBreast surveillanceCause mortalityAnnual mortality rateClinical benefitBreast surgeryInternational registry
2015
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecologic Oncology 2015, 140: 42-47. PMID: 26556769, DOI: 10.1016/j.ygyno.2015.11.009.Peer-Reviewed Original ResearchConceptsBRCA mutation statusLong-term survivalEpithelial ovarian cancerResidual diseaseOvarian cancerMutation carriersMutation statusOntario Cancer RegistryTreatment-related factorsTen-year survivalBRCA2 mutation carriersBRCA1 mutation carriersMajority of womenInitial survival advantageActuarial survivalMortality benefitSerous cancerCancer RegistryBRCA carriersBRCA mutationsMedical recordsBRCA2 mutationsSurvival statusSurvival advantageClinical informationVitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk
Arem H, Yu K, Xiong X, Moy K, Freedman ND, Mayne ST, Albanes D, Arslan AA, Austin M, Bamlet WR, Beane-Freeman L, Bracci P, Canzian F, Cotterchio M, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman PJ, Hartge P, Hassan M, Helzlsouer K, Henderson B, Holly EA, Hoover R, Jacobs EJ, Kamineni A, Klein A, Klein E, Kolonel LN, Li D, Malats N, Männistö S, McCullough ML, Olson SH, Orlow I, Peters U, Petersen GM, Porta M, Severi G, Shu XO, Visvanathan K, White E, Yu H, Zeleniuch-Jacquotte A, Zheng W, Tobias GS, Maeder D, Brotzman M, Risch H, Sampson JN, Stolzenberg-Solomon RZ. Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. PLOS ONE 2015, 10: e0117574. PMID: 25799011, PMCID: PMC4370655, DOI: 10.1371/journal.pone.0117574.Peer-Reviewed Original ResearchConceptsPancreatic cancer riskVitamin D statusCancer riskD statusSingle nucleotide polymorphismsVitamin DPancreatic cancerVitamin D metabolic pathway genesVitamin D metabolic pathwayVitamin D concentrationsUnconditional logistic regressionPancreatic cancer casesVitamin D.Cohort casesCUBN geneEffect modificationPancreatic adenocarcinomaCancer casesD concentrationsLogistic regressionProduct StatisticsRiskTop single nucleotide polymorphismsMultiple comparisonsCancerInfertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal Of Cancer 2015, 112: 925-933. PMID: 25688738, PMCID: PMC4453954, DOI: 10.1038/bjc.2015.24.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskCancer riskInfertility causesOdds ratioElevated endometrial cancer riskEndometrial cancer risk factorsEndometrial Cancer ConsortiumSelf-reported infertilityAdjusted odds ratioCancer risk factorsConfidence intervalsCase-control studyStudy-specific definitionsParous womenEndometrial cancerNulliparous womenPooled analysisNational registryRisk factorsCancer ConsortiumInfertilityNulliparityInfertility concernsInfertility dataLarger study
2014
Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium
Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn‐Ross P, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang Y, Xu W, Yang HP, Yu H, Zeleniuch‐Jacquotte A, Brinton LA. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. International Journal Of Cancer 2014, 136: e410-e422. PMID: 25242594, PMCID: PMC4267918, DOI: 10.1002/ijc.29229.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancer riskIntrauterine deviceEC riskPooled analysisCancer riskLast useCancer ConsortiumOlder ageUse of IUDsMultivariable logistic regressionConfidence intervalsPooled odds ratioCase-control studyInert intrauterine deviceDuration of useHeavy bleedingOdds ratioReversible contraceptivesHormonal changesEC casesReduced riskBiologic effectsUterine environmentLogistic regression
2013
Genome-wide association study of endometrial cancer in E2C2
De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, The Australian National Endometrial Cancer Study Group, Attia J, Black A, Brinton L, Chen C, Chen C, Cook LS, Crous-Bou M, Doherty J, Dunning AM, Easton DF, Friedenreich CM, Garcia-Closas M, Gaudet MM, Haiman C, Hankinson SE, Hartge P, Henderson BE, Holliday E, Horn-Ross PL, Hunter DJ, Le Marchand L, Liang X, Lissowska J, Long J, Lu L, Magliocco AM, McEvoy M, O’Mara T, Orlow I, Painter JN, Pooler L, Rastogi R, Rebbeck TR, Risch H, Sacerdote C, Schumacher F, Scott RJ, Sheng X, Shu XO, Spurdle AB, Thompson D, VanDen Berg D, Weiss NS, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Chanock S, Kraft P. Genome-wide association study of endometrial cancer in E2C2. Human Genetics 2013, 133: 211-224. PMID: 24096698, PMCID: PMC3898362, DOI: 10.1007/s00439-013-1369-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsian PeopleBlack or African AmericanCase-Control StudiesCohort StudiesEndometrial NeoplasmsFemaleGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyHepatocyte Nuclear Factor 1-betaHumansMiddle AgedPolymorphism, Single NucleotideRisk FactorsUnited StatesWhite PeopleConceptsGenome-wide association studiesSingle nucleotide polymorphismsTwo-stage genome-wide association studyAssociation studiesGenome-wide significanceIndependent single nucleotide polymorphismsNovel genetic polymorphismsHNF1B locusGenetic markersEuropean ancestryNovel variantsGenetic polymorphismsGenetic factorsEC susceptibilityPolymorphismLociCommon gynecological malignancyE2C2AncestryReplicationCancerVariantsType I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factorsRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2013, 23: 1010. PMID: 23748177, PMCID: PMC3740723, DOI: 10.1097/igc.0b013e31829a5527.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexHistologic findingsTubal ligationRisk factorsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsDifferent histologic findingsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersMSI-high tumorsBRCA2 mutation statusPolymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4
Leenders M, Bhattacharjee S, Vineis P, Stevens V, Bueno-de-Mesquita HB, Shu XO, Amundadottir L, Gross M, Tobias GS, Wactawski-Wende J, Arslan AA, Duell EJ, Fuchs CS, Gallinger S, Hartge P, Hoover RN, Holly EA, Jacobs EJ, Klein AP, Kooperberg C, LaCroix A, Li D, Mandelson MT, Olson SH, Petersen G, Risch HA, Yu K, Wolpin BM, Zheng W, Agalliu I, Albanes D, Boutron-Ruault MC, Bracci PM, Buring JE, Canzian F, Chang K, Chanock SJ, Cotterchio M, Gaziano JM, Giovanucci EL, Goggins M, Hallmans G, Hankinson SE, Hoffman-Bolton JA, Hunter DJ, Hutchinson A, Jacobs KB, Jenab M, Khaw KT, Kraft P, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Patel AV, Rabe KG, Riboli E, Tjønneland A, Trichopoulos D, Virtamo J, Visvanathan K, Elena JW, Yu H, Zeleniuch-Jacquotte A, Stolzenberg-Solomon RZ. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Cancer Causes & Control 2013, 24: 595-602. PMID: 23334854, PMCID: PMC4127987, DOI: 10.1007/s10552-012-0138-0.Peer-Reviewed Original ResearchConceptsCase-control studyOne-carbon metabolismSingle nucleotide polymorphismsPancreatic cancerOne-carbon biomarkersEuropean Prospective InvestigationCorrelation of SNPsProspective InvestigationFolate intakePancreatic carcinogenesisLarge genetic studiesGene polymorphismsSignificant associationPANCACancerMetabolite levelsGermline variationP-valueMultiple comparisonsAssociationSuggestive associationPolymorphismSuggestive evidenceMetabolismOCM pathwayFlavonoid intake and risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study Cohort
Arem H, Bobe G, Sampson J, Subar AF, Park Y, Risch H, Hollenbeck A, Mayne ST, Stolzenberg-Solomon RZ. Flavonoid intake and risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study Cohort. British Journal Of Cancer 2013, 108: 1168-1172. PMID: 23299536, PMCID: PMC3619057, DOI: 10.1038/bjc.2012.584.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesDietFemaleFlavonoidsHumansMaleMiddle AgedPancreatic NeoplasmsRisk FactorsUnited StatesConceptsPancreatic cancer riskHealth-AARP DietHealth Study cohortFlavonoid intakeCancer riskHazard ratioStudy cohortTotal flavonoid intakeDietary flavonoid intakeIntake of flavonoidsProspective National InstitutesConfidence intervalsPancreatic cancer casesCox proportional hazardsNational InstitutePancreatic cancer carcinogenesisLimited epidemiological studiesSmoking statusInverse associationPancreatic cancerCancer carcinogenesisCancer casesEpidemiological studiesProportional hazardsProtective role
2012
Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium
Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey JV, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu XO, Spurdle AB, Strom BL, Thompson PJ, Ursin G, Webb PM, Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu H, Horn-Ross PL, De Vivo I, Group T. Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal Of Epidemiology 2012, 176: 269-278. PMID: 22831825, PMCID: PMC3491967, DOI: 10.1093/aje/kws129.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancerLast birthCancer ConsortiumLarge pooled analysisTumor histologic subtypeEndometrial cancer riskExogenous hormone useBody mass indexPooled odds ratioCase-control studyYears of ageHormone useHistologic subtypeMass indexPooled analysisRisk factorsEffect modificationOdds ratioDiagnosis groupsProtective associationCancer riskLower riskNumber of birthsOlder ageFunctional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer
Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012, 33: 2119-2125. PMID: 22822098, DOI: 10.1093/carcin/bgs243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCircular DichroismCohort StudiesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsNucleic Acid ConformationOvarian NeoplasmsPolymorphism, Single NucleotidePrognosisPromoter Regions, GeneticQuantitative Trait LociReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerRNA-Binding ProteinsSurvival RateConceptsSingle nucleotide polymorphismsOvarian cancerEpithelial ovarian cancer survivalCancer-related risk factorsEpithelial ovarian cancerOvarian cancer survivalOvarian cancer prognosisHigher mortality riskCell-associated markersPrimary EOC tissuesLin-28BStem cell-associated markersAssociation of genotypesDominant modelPatient survivalSurvival outcomesBorderline significanceEOC tissuesCancer survivalRisk factorsReal-time PCRMortality riskCancer prognosisMultivariate analysisPotential biomarkers
2011
Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis
Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow W, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology 2011, 142: 442-452.e5. PMID: 22108196, PMCID: PMC3488768, DOI: 10.1053/j.gastro.2011.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalAustraliaCanadaCase-Control StudiesCohort StudiesEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansLogistic ModelsMaleMiddle AgedOdds RatioRisk AssessmentRisk FactorsStomach NeoplasmsTime FactorsUnited StatesYoung AdultConceptsNonsteroidal anti-inflammatory drugsEsophagogastric junctional adenocarcinomaRisk of EACNSAID useEsophageal adenocarcinomaPooled analysisOdds ratioEsophagogastric junctionNonaspirin nonsteroidal anti-inflammatory drugsStudy-specific odds ratiosRandom-effects meta-analysis modelEffects meta-analysis modelPrevention of adenocarcinomaUse of aspirinSignificant reduced riskPopulation-based studyConfidence intervalsAnti-inflammatory drugsDuration of useEsophageal Adenocarcinoma ConsortiumMeta-analysis modelLogistic regression modelsJunctional adenocarcinomaMedication typeEAC riskClinical impact of unclassified variants of the BRCA1 and BRCA2 genes
Akbari MR, Zhang S, Fan I, Royer R, Li S, Risch H, McLaughlin J, Rosen B, Sun P, Narod SA. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. Journal Of Medical Genetics 2011, 48: 783. PMID: 21965345, DOI: 10.1136/jmedgenet-2011-100305.Peer-Reviewed Original ResearchConceptsFirst-degree relativesFemale first-degree relativesRelatives of patientsOvarian cancerCumulative riskPathogenic mutationsUnclassified variantsRisk of cancerHistorical cohortBRCA2 mutationsClinical impactHigh riskBRCA2 genesCancerUnknown significancePatientsMissense variantsFunctional effectsWomenRiskBRCA1PenetranceMutationsRelativesCohortLong‐term overweight and weight gain in early adulthood in association with risk of endometrial cancer
Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, Rutherford T, Yu H. Long‐term overweight and weight gain in early adulthood in association with risk of endometrial cancer. International Journal Of Cancer 2011, 129: 1237-1243. PMID: 21387312, PMCID: PMC3125463, DOI: 10.1002/ijc.26046.Peer-Reviewed Original ResearchConceptsBody mass indexLong-term overweightEndometrial cancerSubstantial weight gainWeight gainBody weightPopulation-based case-control studyHigher body mass indexEndometrial cancer riskWeight changeDisease 10 yearsEarly adulthoodUnconditional logistic regressionAdult lifeCase-control studyTime of interviewSuch weight changesMass indexNormal weightIncident casesRisk factorsOdds ratioLong-term effectsAge 40Cancer risk
2010
Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality
Zhou Y, Irwin ML, Risch HA. Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality. Gynecologic Oncology 2010, 120: 209-213. PMID: 21106231, PMCID: PMC3034401, DOI: 10.1016/j.ygyno.2010.10.035.Peer-Reviewed Original ResearchConceptsOvarian cancer mortalityCancer mortalityTime pointsWeight changeHigh riskPost-diagnosis body mass indexOvarian cancer-specific mortalityBMI 5 yearsCancer-specific mortalityInterview-administered questionnaireProportional hazards regressionBody mass indexEpithelial ovarian cancerCause mortalityHazards regressionMass indexSpecific mortalityOvarian cancerBMISurvival rateMortalityWeight gainDiagnosisStrong associationWomenA genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 2010, 42: 224-228. PMID: 20101243, PMCID: PMC2853179, DOI: 10.1038/ng.522.Peer-Reviewed Original Research
2009
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox Jr J, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009, 41: 986-990. PMID: 19648918, PMCID: PMC2839871, DOI: 10.1038/ng.429.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAllelesCase-Control StudiesChromosomes, Human, Pair 9Cohort StudiesFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic VariationGenome-Wide Association StudyGenotypeHaplotypesHumansIntronsLinkage DisequilibriumLogistic ModelsMaleOdds RatioPancreatic NeoplasmsPolymorphism, Single NucleotideProspective StudiesRisk FactorsUnited States